Tone mix
Week by week 52 weeks
Oct 27, 2025Oct 19, 2026
Share of Moderna, Inc. Common Stock's 1,427 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Sep 28, 2026 · tone -10Prediction: Moderna Stock Will Soar 100% by 2030-76
- Week of May 25, 2026 · tone -32Moderna Inc. (NASDAQ: MRNA) Stock Under Pressure as mRNA Platform Seeks New Applications-70
- Week of Mar 2, 2026 · tone +42Moderna Resolves Global Patent Litigation with Arbutus/Genevant+56
- Week of Nov 17, 2025 · tone +58Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates+50
- Week of Oct 19, 2026 · tone -22Moderna Named a Top Employer by Science for Twelfth Consecutive Year-49
- Week of Sep 7, 2026 · tone +23If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.)-48
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Session tone8-session averageHeadlines
Each point is the average score of the headlines about Moderna, Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 67 | -10 |
| Last 30 sessions | 158 | +15 |
| Last 90 sessions | 604 | +54 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Thursday, October 29, 2026
4 headlines, average tone +38: 2 positive, 2 neutral and 0 negative. Showing all 4.
- www.fool.com · 2 outletsWill Moderna Soar on Nov. 6? | The Motley FoolNeutral
- www.fool.com · 2 outletsAxsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp VolatilityNeutral
- 247wallst.com · 1 outletModerna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge HigherPositive
- www.hindustantimes.com · 1 outletHere's Why Moderna's CEO Isn't Fazed by Its Cancer-Vaccine SelloffPositive
Show the table · 4 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Will Moderna Soar on Nov. 6? | The Motley Fool | www.fool.com | 2 | Neutral |
| Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility | www.fool.com | 2 | Neutral |
| Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher | 247wallst.com | 1 | Positive |
| Here's Why Moderna's CEO Isn't Fazed by Its Cancer-Vaccine Selloff | www.hindustantimes.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 28, 2026
7 headlines, average tone -7: 2 positive, 2 neutral and 3 negative. Showing all 7.
- www.ualrpublicradio.org · 7 outletsModerna and Merck's mRNA vaccine reduces melanoma recurrence by 42%Positive
- www.tickerreport.com · 1 outletFY2030 EPS Forecast for Moderna Cut by AnalystNegative
- seekingalpha.com · 1 outletModerna stock falls as William Blair downgrades (MRNA:NASDAQ)Negative
- www.proactiveinvestors.com · 1 outletScancell cancer vaccine strategy backed by Moderna and Merck trial resultsPositive
- article.wn.com · 1 outletModerna Cancer Vaccine Trial, 42% Recurrence Drop & Key Reality CheckNegative
- www.themarketsdaily.com · 1 outlet13,296 Shares in Moderna, Inc. $MRNA Bought by Great Lakes Retirement Inc.Neutral
- www.bostonglobe.com · 1 outletModerna CEO on what's next after success in cancer vaccineNeutral
Show the table · 7 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Moderna and Merck's mRNA vaccine reduces melanoma recurrence by 42% | www.ualrpublicradio.org | 7 | Positive |
| FY2030 EPS Forecast for Moderna Cut by Analyst | www.tickerreport.com | 1 | Negative |
| Moderna stock falls as William Blair downgrades (MRNA:NASDAQ) | seekingalpha.com | 1 | Negative |
| Scancell cancer vaccine strategy backed by Moderna and Merck trial results | www.proactiveinvestors.com | 1 | Positive |
| Moderna Cancer Vaccine Trial, 42% Recurrence Drop & Key Reality Check | article.wn.com | 1 | Negative |
| 13,296 Shares in Moderna, Inc. $MRNA Bought by Great Lakes Retirement Inc. | www.themarketsdaily.com | 1 | Neutral |
| Moderna CEO on what's next after success in cancer vaccine | www.bostonglobe.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 27, 2026
5 headlines, average tone -10: 2 positive, 0 neutral and 3 negative. Showing all 5.
- www.investors.com · 2 outletsModerna Stock Recovers From 10% Dive, But Muted Expectations Haunt Cancer VaccineNegative
- www.el-balad.com · 1 outletModerna advances bird flu trial in Influenza Vaccine Recommendations Over 50Positive
- 247wallst.com · 1 outletModerna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds SteadyNegative
- www.aol.com · 1 outletModerna's Rally May Have Run Out of Steam. Here's What to Watch NextNegative
- freerepublic.com · 1 outletModerna's mRNA flu vaccine approved by FDA. When is it available? [heads up]Positive
Show the table · 5 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Moderna Stock Recovers From 10% Dive, But Muted Expectations Haunt Cancer Vaccine | www.investors.com | 2 | Negative |
| Moderna advances bird flu trial in Influenza Vaccine Recommendations Over 50 | www.el-balad.com | 1 | Positive |
| Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady | 247wallst.com | 1 | Negative |
| Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next | www.aol.com | 1 | Negative |
| Moderna's mRNA flu vaccine approved by FDA. When is it available? [heads up] | freerepublic.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 26, 2026
23 headlines, average tone -4: 8 positive, 5 neutral and 10 negative. The 8 most widely carried stories are listed; the table holds all 23.
- abcnews4.com · 60 outletsModerna-Merck personalized mRNA melanoma vaccine cuts relapse risk in late-stage trialPositive
- www.ualrpublicradio.org · 22 outletsMerck and Moderna release promising data on cancer vaccine trialPositive
- www.newjerseytelegraph.com · 2 outletsModerna Named a Top Employer by Science for Twelfth Consecutive YearPositive
- www.themarketsdaily.com · 2 outletsModerna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 TrialPositive
- www.fool.com · 2 outletsModerna's Stock Just Stumbled. Is It a Buy on the Dip?Negative
- www.investors.com · 2 outletsMerck And Moderna Diverge On Cancer Vaccine Results; Do They Still Have A Drug?Negative
- www.aol.com · 1 outletModerna stock extends decline after leaked data on melanoma vaccine trialNegative
- econotimes.com · 1 outletModerna Shares Fall 17.57% After Melanoma Trial Results Surface EarlyNegative
Show the table · 23 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Moderna-Merck personalized mRNA melanoma vaccine cuts relapse risk in late-stage trial | abcnews4.com | 60 | Positive |
| Merck and Moderna release promising data on cancer vaccine trial | www.ualrpublicradio.org | 22 | Positive |
| Moderna Named a Top Employer by Science for Twelfth Consecutive Year | www.newjerseytelegraph.com | 2 | Positive |
| Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial | www.themarketsdaily.com | 2 | Positive |
| Moderna's Stock Just Stumbled. Is It a Buy on the Dip? | www.fool.com | 2 | Negative |
| Merck And Moderna Diverge On Cancer Vaccine Results; Do They Still Have A Drug? | www.investors.com | 2 | Negative |
| Moderna stock extends decline after leaked data on melanoma vaccine trial | www.aol.com | 1 | Negative |
| Moderna Shares Fall 17.57% After Melanoma Trial Results Surface Early | econotimes.com | 1 | Negative |
| Moderna's Cancer Vaccine Success Falls Short of Early Expectations | www.bgnes.com | 1 | Negative |
| Baystreet.ca - Moderna Wins Top Employer Status | baystreet.ca | 1 | Positive |
| Moderna, Merck's cancer vaccine data a major advancement | www.cnbc.com | 1 | Positive |
| Moderna, Merck cancer vaccine met key endpoints in melanoma trial, detailed data confirm | www.bostonglobe.com | 1 | Positive |
| Moderna's Cancer Vaccine Trial Data Raises Concerns Among Investors | udaipurkiran.com | 1 | Negative |
| Analysts weigh in on Moderna's big drop following cancer vaccine results | seekingalpha.com | 1 | Negative |
| Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip | www.aol.com | 1 | Negative |
| Moderna Cancer Vaccine Data Confirms 42% Recurrence Cut | www.financial-news.co.uk | 1 | Positive |
| Oncologists cheer melanoma data that tanked Moderna's shares | www.spokesman.com | 1 | Negative |
| Moderna's melanoma vaccine succeeds in major trial. So why did its stock plunge? | www.ynetnews.com | 1 | Negative |
| Notable healthcare headlines for the week: Moderna, Roche and Abbott Laboratories in focus | seekingalpha.com | 1 | Neutral |
| Moderna's cancer vaccine is 'likely' to get approved. Skeptics question if it will be the best option. | www.morningstar.com | 1 | Neutral |
| Moderna investors should brace for more whiplash | www.hindustantimes.com | 1 | Neutral |
| Breakfast News: A Conversation With Moderna's CEO | www.fool.com | 1 | Neutral |
| Hyperliquid Prices Moderna Futures at $190.53 During U.S. Market Closure | econotimes.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 23, 2026
23 headlines, average tone -36: 6 positive, 2 neutral and 15 negative. The 8 most widely carried stories are listed; the table holds all 23.
- www.hawaiitelegraph.com · 3 outletsModerna Named a Top Employer by Science for Twelfth Consecutive YearPositive
- www.investors.com · 2 outletsDow Jones Futures: Moderna Crashes, Meta Fuels AI Meltdown, But Warren Buffett Market ThrivingNegative
- www.finanzen.ch · 2 outletsMerck, Moderna Personalized MRNA Caner Vaccine Cuts Melanoma Recurrence Risk In Phase 3 StudyPositive
- www.investors.com · 1 outletModerna Stock Crashes 20% On Reportedly Leaked Cancer Vaccine DataNegative
- www.financial-news.co.uk · 1 outletModerna stock plunges 25% after melanoma vaccine data leakNegative
- www.fool.com · 1 outletStock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak ReportsNegative
- www.cnbc.com · 1 outletModerna stock falls after cancer vaccine data leakNegative
- economictimes.indiatimes.com · 1 outletModerna shares plummet 25%, loses about $24 billion after cancer vaccine data leakNegative
Show the table · 23 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Moderna Named a Top Employer by Science for Twelfth Consecutive Year | www.hawaiitelegraph.com | 3 | Positive |
| Dow Jones Futures: Moderna Crashes, Meta Fuels AI Meltdown, But Warren Buffett Market Thriving | www.investors.com | 2 | Negative |
| Merck, Moderna Personalized MRNA Caner Vaccine Cuts Melanoma Recurrence Risk In Phase 3 Study | www.finanzen.ch | 2 | Positive |
| Moderna Stock Crashes 20% On Reportedly Leaked Cancer Vaccine Data | www.investors.com | 1 | Negative |
| Moderna stock plunges 25% after melanoma vaccine data leak | www.financial-news.co.uk | 1 | Negative |
| Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports | www.fool.com | 1 | Negative |
| Moderna stock falls after cancer vaccine data leak | www.cnbc.com | 1 | Negative |
| Moderna shares plummet 25%, loses about $24 billion after cancer vaccine data leak | economictimes.indiatimes.com | 1 | Negative |
| Moderna Stock Plunges 18% As Leaked Melanoma Vaccine Data Underperforms | www.rttnews.com | 1 | Negative |
| Moderna shares plunge as leaked cancer vaccine data disappoints | www.afr.com | 1 | Negative |
| Dow Jones Top Company Headlines at 7 PM ET: Moderna's Stock Plummets After Cancer-Vaccine Data Shared on Social Media | American ... | www.morningstar.com | 1 | Negative |
| US stocks 2026: Moderna, SanDisk lead top 10 gainers delivering up to 734% returns | economictimes.indiatimes.com | 1 | Positive |
| Moderna shares sink over 25% as cancer vaccine data triggers 'sell-the-news' retreat | www.theglobeandmail.com | 1 | Negative |
| Moderna, Merck shares fall on eagerly anticipated cancer vaccine results | www.biopharmadive.com | 1 | Negative |
| Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42% | arstechnica.com | 1 | Positive |
| Moderna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat | www.ksl.com | 1 | Negative |
| Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42% | www.ajmc.com | 1 | Positive |
| Details of Moderna's Breakthrough Cancer Vaccine Got Leaked. Its Stock is Plunging. | www.ibtimes.com | 1 | Negative |
| Moderna Shares Fall 17.57%, Leaving Year-to-Date Gain at 587% | econotimes.com | 1 | Negative |
| Moderna mRNA vaccine almost halves the risk of skin cancer returning | www.nature.com | 1 | Positive |
| Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall | www.ksl.com | 1 | Negative |
| Stocks making the biggest moves premarket: AT&T, SpaceX, Moderna, Deckers, Bloom Energy and more | www.cnbc.com | 1 | Neutral |
| Here's what Moderna's latest mRNA cancer vaccine data actually show | www.scientificamerican.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Moderna, Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.